BIVI - BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer's Disease Today September 7 2023 | Benzinga
CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, is hosting today a virtual KOL event titled NE3107?Putting Data in Context, ahead of the upcoming Phase 3 results in Alzheimer's Disease. The event will take place today at 2:30pm ET. To register, click here.
The event will focus on BioVie's lead product candidate, NE3107, currently in a potentially pivotal Phase 3 study in patients with mild to moderate Alzheimer's disease with expected topline data readout in the fourth quarter of 2023. The company's leadership team and Key Opinion Leader (KOL) Steven E. Arnold, MD (Harvard Medical School; Massachusetts General Hospital) will discuss the totality of NE3107 data generated to date including:
- The role of neuroinflammation and insulin resistance in Alzheimer's Disease pathology.
- The potential for NE3107 to have an active epigenetic effect associated with improvements in inflammation, insulin signaling, and other critical biological processes in a manner that is significantly correlated to improvements in cognition.
- An overview of results observed in the NE3107 Phase 2 exploratory biomarker study.
A live question and answer session will follow the formal presentations.
About Steven E. Arnold, MD
After receiving his MD from Boston University, Dr. Arnold completed residency training in Psychiatry at the New York State Psychiatric Institute / Columbia Presbyterian Medical Center in New York, residency training in Neurology and fellowship training in Behavioral Neurology at the University of Iowa Hospitals and Clinics in Iowa City. Dr. Arnold is board certified in both neurology and psychiatry. At ...